Day 2 - CT (China Time, GMT+08:00)
Darwin Biotech (Series D) The Opportunity Darwin Biotech is a clinical-stage biopharmaceutical company (est. 2016) disrupting the regenerative medicine space. We have moved beyond traditional cell therapy to develop a first-in-class, cell-free, protein complex platform targeting the world’s most devastating neurological diseases. The ALT001 Breakthrough Our lead program, ALT001, represents a paradigm shift in Central Nervous System (CNS) treatment: Dual-Action Efficacy: The first drug candidate to achieve both biomarker reduction (disease modification) and functional restoration in ALS patients. Scalability: Leverages proprietary technology to manufacture standardized protein complexes at an industrial scale, overcoming the traditional hurdles of cell-based therapies. Clinical Validation: Positive data from randomized, double-blind, placebo-controlled IIT studies demonstrate superiority over currently approved or late-stage investigational ALS drugs. Clinical Pipeline & Key Milestones ALS (China): Phase 1 initiated (IND Dec 2025); Target NDA 2027. ALS (USA): IND submission Jan 2026; Target NDA 2028. Stroke (China): IND submitted Dec 2025 for acute and convalescent stages. Expansion: Active programs in Alzheimer’s (AD) and rare diseases (MSA, CADASIL). Investment & Growth We recently closed a $143M USD Series D round to capitalize on our clinical momentum. These funds are strictly earmarked for: 1.Executing the ALS Regulatory Path: Completing China clinical trials and the US IND/clinical launch. 2.Platform Expansion: Pushing Stroke and AD programs through critical clinical inflection points. 3.Manufacturing Leadership: Maintaining our industrial-level standardization edge. Investment Thesis Darwin Biotech is uniquely positioned to capture the neuro-restorative market. With a de-risked lead asset (ALT001), a clear regulatory roadmap toward Accelerated Approval, and a robust $143M capital cushion, we are engineering the future of CNS medicine.
Lysoway Therapeutics is a biotechnology company pioneering lysosomal ion-channel modulators for neurodegenerative and lysosomal disorders. Using proprietary screening platforms and structure-guided design technologies, the company develops highly brain-penetrant, selective, and potent small-molecule modulators targeting key lysosomal ion channels, including TRPML1 and TMEM175. Lysoway’s approach aims to restore autophagy-lysosomal function, re-establish cellular homeostasis, and address upstream disease mechanisms in conditions such as Alzheimer’s disease, Parkinson’s disease, and other age-related or rare lysosomal disorders.
Highslab focuses on innovation driven by the combination of mRNA display and artificial intelligence, and is committed to developing breakthrough cyclic peptide drugs. Executive Summary: (1) Proprietary integrated mRNA display and AI driven drug discovery platform focused on oral macrocyclic peptide. (2) Novel cyclization of mRNA display macrocyclic peptide to restrict the conformation of the macrocyclic peptides, thereby significantly improving peptide druggability. (3) Powerful prediction on protein and macrocyclic peptides complex by our HighFold models (based on AlphaFold series) that cover all natural amino acids and the majority of unnatural amino acids and prediction on oral druggability that covers the stability and cell membrane penetration of macrocyclic peptide. (4) Pioneering de novo design AI models for macrocyclic peptide hits discovery and optimization. (5) Two series of IL-23R oral peptides generated from our macrocyclic peptide drug discovery platform exhibited much better PK and in vitro activities than JNJ2113, providing a solid validation of both our mRNA display platform and AI platform for oral peptide drug discovery.
Resolve is a mid-stage biopharma company developing first-in-class biologic drugs that address acute and chronic inflammation.
InCSD, LLC is a global consulting firm specializing in innovative clinical trial design, advanced statistical methodologies, and biometrics strategy for the pharmaceutical and biotechnology industries. With more than three decades of leadership experience across rare diseases, oncology, and complex Phase 2/3 programs, InCSD integrates adaptive and model-informed design, PK/PBPK modeling, and regulatory strategy to accelerate development and strengthen submission readiness. Our inspection-ready Quality Management System (QMS) ensures systematic oversight, document traceability, and regulatory compliance for every engagement. Clients benefit from direct access to senior scientific and regulatory experts who provide proactive, data-driven solutions and real-time collaboration. By partnering with InCSD, sponsors gain a strategic, flexible, and quality-focused partner committed to delivering scientifically robust, regulatorily sound, and operationally efficient outcomes—maximizing the probability of clinical and regulatory success while minimizing risk.
ChemPartner is a global CRO providing integrated drug discovery and development services from target identification through IND. With operations across China, the US, and Europe, we support biotech and pharmaceutical companies with high-quality, cost-effective, and science-driven solutions. Our multidisciplinary teams combine biology, chemistry, DMPK, and translational sciences to accelerate innovation and enable efficient global development programs.
Chiima Therapeutics is a pre-clinical, early-stage biotech company committed to developing innovative therapies that focus on women’s health. We are currently investigating our lead compound, CHM-001 for the non-hormonal treatment of moderate to severe endometriosis-related pain in adult women. This compound has robust IP protection that includes disease-modifying effects and a paid reduction in endometriosis. We conducted our final meeting with the US Patent & Trademark Office to secure a composition of matter and method of treatment patent for patients with endometriosis. Endometriosis-related pain control is a significant clinical challenge that has been largely unmet. Endometriosis affects an estimated 1 in 10 women during their reproductive years, which is approximately 200 million women in the world. Our other lead compound, CHM-002 is being investigated for the treatment of pre-term labor. In the United States, preterm delivery affects approximately 1 in 10 births and is the cause of at least 75% of neonatal deaths. Approximately 15 million preterm neonates are born annually and more than 1 million die from subsequent complications within the following 5 years. Our pre-clinical data in both molecules have demonstrated positive Proof of Concept and efficacy data and a tolerable safety profile. We are currently finalizing our IND studies, preparing for clinical phase 1 first in human use, and continuing our pre-IND meeting conversations with the FDA and pre-CTA meetings with EMA. We also have a pre-NDA meeting with The National Medical Products Administration of China in Q2. The Global endometriosis market is forecast to reach USD 3.9 Billion by 2026. The global market for preterm birth was valued at $1.3 billion in 2022. The market is expected to grow to $2.6 billion by 2030. Chiima Therapeutics is looking to raise 8MM in seed funding round for commercial growth and accelerating pipeline product development. We are also looking to do a potential partnership.
We are an R&D driven, AI-powered biopharma company committed to improving people's lives and creating compelling growth.
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
ATLATL is the First Stop in China—an Asia-Pacific network of innovation centers and a portal to assets, on-site R&D execution, and deals. Our bio-hubs offer integrated labs, core facilities, and hands-on R&D support. ATLATL scientists work side-by-side with embedded CRO teams and instrument-company experts as one execution team—moving fast, troubleshooting in real time, and generating rapid proof-of-concept data. We partner with MNCs to source and evaluate China assets, accelerate diligence, and structure collaborations and licensing transactions. We also co-incubate and invest—accelerating commercialization from idea to market.